Vivek Ramaswamy's Arbutus kills another program over safety, stock takes another hit
Vivek Ramaswamy and Roivant’s $100 million bet on Arbutus and their hepatitis B pipeline have seen better days.
Ramaswamy made the bet in 2017 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
